Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Operating Expenses: 2022-2025

Historic Operating Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $48.7 million.

  • Entrada Therapeutics' Operating Expenses rose 18.04% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.1 million, marking a year-over-year increase of 16.28%. This contributed to the annual value of $163.8 million for FY2024, which is 23.90% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Operating Expenses stood at $48.7 million, which was down 0.27% from $48.8 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Operating Expenses peaked at $48.8 million during Q2 2025, and registered a low of $22.2 million during Q1 2022.
  • In the last 3 years, Entrada Therapeutics' Operating Expenses had a median value of $41.2 million in 2024 and averaged $39.6 million.
  • Data for Entrada Therapeutics' Operating Expenses shows a peak YoY skyrocketed of 46.17% (in 2023) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Operating Expenses (Quarterly) stood at $25.6 million in 2022, then spiked by 44.43% to $36.9 million in 2023, then rose by 17.11% to $43.3 million in 2024, then increased by 18.04% to $48.7 million in 2025.
  • Its Operating Expenses was $48.7 million in Q3 2025, compared to $48.8 million in Q2 2025 and $42.3 million in Q1 2025.